Contact
searchSearch
HMP Global
Login
Quiz

Sotorasib Plus Panitumumab and FOLFIRI for Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer

07/23/2025

Related Content

News
Adagrasib Plus Cetuximab Does Not Improve Progression-Free or Overall Survival Over Chemotherapy in KRAS G12C–Mutated Metastatic Colorectal Cancer
07/07/2026
Stephanie Holland
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did...
07/07/2026
Oncology
Ramón Salazar, MD, PhD
Videos
Anti-EGFR–First Strategy Demonstrates Superior Initial Disease Control in Patients With Metastatic Colorectal Cancer
06/09/2026
Ramon Salazar, MD, PhD
Ramón Salazar, MD, PhD, discusses results from the phase 3 CR-SEQUENCE trial showing that first-line panitumumab-based therapy significantly improved response rates and progression-free survival compared with a bevacizumab-first strategy in...
Ramón Salazar, MD, PhD, discusses results from the phase 3 CR-SEQUENCE trial showing that first-line panitumumab-based therapy significantly improved response rates and progression-free survival compared with a bevacizumab-first strategy in...
Ramón Salazar, MD, PhD,...
06/09/2026
Oncology
Filippo Pietrantonio, MD
Videos
ctDNA Clearance Predicts Outcomes in KRAS G12C-Mutated Metastatic Colorectal Cancer
06/09/2026
Filippo Pietrantonio, MD
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD,...
06/09/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib and Cetuximab Plus FOLFIRI Improves Outcomes in BRAF V600E-Mutant Metastatic Colorectal Cancer
06/04/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO,...
06/04/2026
Oncology

Recent News

News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology
News
Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
09/15/2026
Emily Estrada
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3...
09/15/2026
Oncology
News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use